



Annual Report and Audited Financial Statements for the year ended 30 June 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Contents	Page
General Information	3
Investment Manager's Report	4
Directors' Report	5
Independent Auditor's Report	7
Custodian's Report	10
Supplementary Information	11
Portfolio Statement	12
Statement of Financial Position	13
Statement of Comprehensive Income	14
Statement of Cash Flows	15
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	16
Notes to the Financial Statements	17



Annual Report and Audited Financial Statements for the year ended 30 June 2023

General Information

Address and Registered Office

PO Box 255

Trafalgar Court, Les Banques St Peter Port, Guernsey

GY1 301

Channel Islands

Investment Manager

Momentum Global Investment Management Limited

The Rex Building

62 Queen Street

London

EC4R 1EB

United Kingdom

Distribution Partner

The Portfolio Bureau (Pty) Ltd

Suite 1502 15th Floor

Portside 4, Bree Street,

Cape Town

8001

South Africa

Manager

Momentum Wealth International Limited

La Plaiderie House

La Plaiderie

St Peter Port, Guernsey

GY1 1WF

Channel Islands

Custodian

Northern Trust (Guernsey) Limited

PO Box 71

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY13DA

Channel Islands

Directors of the Incorporated Cell

Robert Alastair Rhodes

Roxanne Power

Marie Curutchet

Ferdinand van Heerden

Ray Mhere - appointed 25 May 2023

Kapil Joshi - resigned 25 May 2023

Administrator, Registrar & Secretary

Northern Trust International Fund Administration

Services (Guernsey) Limited

PO Box 255

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY1 3QL

Channel Islands

Legal Advisor

Carey Olsen

Carey House

Les Banques

St Peter Port, Guernsey

GY1 4BZ

Channel Islands

Independent Auditor

Ernst & Young LLP

PO Box 9

Royal Chambers

St Julian's Avenue

St Peter Port, Guernsey

GY1 4AF

Channel Islands

Sub-Investment Manager

The Portfolio Bureau Investments (Pty) Ltd

Suite 1502 15th Floor

Portside 4, Bree Street,

Cape Town

8001

South Africa



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Investment Manager's Report

Performance

After some ups and downs in 2022, global equity markets rallied strongly into mid-year 2023 (MSCI World +15.1% YTD and 18.5% over 12 months) with the threat of a US government debt default safely avoided and a pause in rate hikes from the United States Federal Reserve (the "Fed") (after ten consecutive rate hikes) buoying equity markets. Megacap US-listed tech stocks remain a key driver of equity market returns benefitting from the hype surrounding artificial intelligence ("AI"). Emerging markets have lagged developed markets materially over the past 12 months with Chinese companies the biggest laggards in the face of a disappointing rebound in Chinese economic activity, after initial optimism post its economic re-opening in late 2022. Against this backdrop PB Global Flexible Fund IC Limited (the "Fund") returned 7.2% net of all fees over the 12 months ending 30 June 2023, compared to 9.8% for the Fund's composite benchmark and 5.1% for the EAA Fund USD Flexible Allocation peer group average. The Fund's outperformance against the peer group average over the past 12 months stems mainly from an underweight bond exposure, as bonds underperformed the other asset classes, and strong relative outperformance from a number of underlying managers. There were particularly strong relative performances from the Orbis Global Balanced fund (12.7%) and the Nedgroup Core Global fund managed by Blackrock (9.9%) against their respective category averages of 5.1% and 7.7%.

Portfolio Changes

The Fund's asset allocation positioning increasingly turned more defensive over the course of the past year, as the manager became more concerned about recession risk in the US combined with high equity valuations. The Fund's equity exposure ended the 12-month period on 56.3% at 30 June 2023, approximately 7% lower than the level at which it started the 12 month period under review. Bond exposure at 30%, as at 30 June 2023, is on benchmark and materially higher than the 18.4% exposure at the start of the 12 month period. At the manager level, some minor rebalancing occurred between some managers during the period.

Looking Forward

We expect the second half of the year 2023 to remain challenging. Equity markets have been narrowly driven, and valuations of the dominant stocks, big tech, have become stretched. Outside big tech, valuations are more reasonable but face increasingly tough economic headwinds as the long stretch of monetary tightening finally begins to bite. Markets do not seem to be braced for the risk of an earnings downturn and a potential hard landing. The immediate outlook calls for continuing caution, but the sharp rises in interest rates and bond yields are generating the best opportunities in safe-haven government bond markets in many years. We observe that underlying balanced fund managers are adding to their bond holdings. We remain patient before adding to risk assets, but are looking for opportunities to add to duration in fixed income, taking advantage of the attractive returns now available, as we wait for the turn in the economic and market cycle which we expect to be in sight as we enter 2024. We will maintain a cautious to neutral stance in the portfolio in the short-term but assess opportunities as they start to emerge.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Directors' Report

The Directors present their annual report together with the audited financial statements of PB Global Flexible Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2023.

Principal

The Cell with company number 56162 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 17.

Going concern

The Directors have made an assessment of going concern including consideration of geo-political issues on the Cell. Refer to note 2 for the detailed disclosure.

Directors

The Directors of the Cell during the year and at the date of this report are set out on page 3.

Directors' interests

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Incorporated Cell for that period. In preparing these financial statements the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell has complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Directors' Report (continued)

Directors' responsibilities (continued)

The annual report together with the audited financial statements of the Incorporated Cell is published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent auditors

Ernst & Young LLP have indicated their willingness to continue in office. The reappointment of Ernst & Young LLP will be proposed within the next written resolution to deal with annual business.

Marie Curutchet

Director

30 November 2023

Robert Rhodes

Director



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of PB Global Flexible Fund IC Limited

Opinion

We have audited the financial statements of PB Global Flexible Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2023 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 16, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2023 and of its profit for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2024.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of PB Global Flexible Fund IC Limited (continued)

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell
 and determined that the most significant are those that relate to the reporting framework (International Financial
 Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey)
 Law, 2020);
- We understood how the Incorporated Cell is complying with those frameworks by making enquiries of
 management and those responsible for compliance matters and corroborated this by reviewing minutes of
 meetings of the Board of Directors and correspondence between the Incorporated Cell and the Guernsey Financial
 Services Commission. We gained an understanding of the Board's approach to governance, demonstrated by its
 review of compliance reports, the investment manager's reports and internal control processes;



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of PB Global Flexible Fund IC Limited (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how fraud might occur by considering the risk of management override and by identifying the valuation of investments (specifically manual price overrides) and the recognition of dividend income at year-end (cut-off) as fraud risks. We considered the controls the Incorporated Cell has established to address the risk identified by the directors or that otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor those controls. We also considered the existence of any stakeholder influences which may cause management to seek to manipulate the financial performance and did not note any;
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
 regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of
 compliance reports; review of correspondence with the Guernsey Financial Services Commission; making inquiries
 of those charged with governance; and performance of journal entry testing based on our risk assessment and
 understanding of the business, with a focus on non-standard journals and those relating to areas with an identified
 associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

Ernst & Karryll

4753914588A54C3... Ernst & Young LLP

Guernsey, Channel Islands

Date: 04 December 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Custodian's Report to the Members of PB Global Flexible Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2023 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

For and on behalf of

Northern Trust (Guernsey) Limited

30 November 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Supplementary Information

		30.06.23	30.06.22
1.	NUMBER OF SHARES OUTSTANDING Class A	73,556,778	73,632,968
2.	NET ASSET VALUE PER SHARE - USD Class A	1.41	1.31
3.	HIGHEST/LOWEST PRICE - USD* Class A	1.42/1.24	1.53/1.30
4.	NUMBER OF SHARES SUBSCRIBED Class A	2,805,543	5,278,539
5.	NUMBER OF SHARES REDEEMED Class A	2,881,733	1,669,028

^{*}The highest/lowest price for the Cell is based on prices from prior year end to current year end, being 30 June 2023.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Portfolio Statement

		% of Net
Holdi	ngs Fair Value	e Assets
Financial assets at fair value through profit or loss	<u>USI</u>	<u>)</u>
Collective Investment Schemes: 97.23% (2022: 98.86%)		
Asset Allocation Funds		
Coronation Global Capital Plus Fund 638,	261 8,870,998	8.54
Coronation Global Managed Fund Class P 551,	325 8,126,416	5 7.82
Foord International Fund 151,	775 7,456,423	3 7.18
Nedgroup Investments Funds Core Global Fund Class C 14,392,	633 21,295,339	9 20.50
Ninety One Global Strategy Fund - Global Multi-Asset Income Fund Class I 546,	384 14,888,97	7 14.33
Ninety One Global Strategy Fund - Global Strategic Managed Fund Class I 283,	634 10,103,032	9.72
Orbis SICAV Global Balanced Fund Investor Share Class 521,	881 9,988,79	9.62
Total Asset Allocation Funds	80,729,978	77.71
Equity Funds		
Fundsmith Equity Fund Feeder 102,	, ,	
	251 11,137,28	
,	654 5,677,063	
Total Equity Funds	20,279,59	1 19.52
Total Callastiva Invastracy t Calcaras	101 000 50	07.22
Total Collective Investment Schemes	101,009,569	97.23
Financial assets at fair value through profit or loss	101,009,569	97.23
Other Net Assets: 2.77% (2022: 1.14%)	2,877,790	2.77
Net Assets Attributable to Holders of Participating Redeemable Shares	103,887,359	9 100.00



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Financial Position

		Year ended	Year ended
		30.06.23	30.06.22
	Notes	<u>USD</u>	<u>USD</u>
ASSETS			
CURRENT ASSETS			
Financial assets at fair value through profit or loss	6	101,009,569	95,277,866
Cash and cash equivalents	7	2,988,904	1,217,145
Deposit interest receivable		7,490	-
Other receivables	8 _	402	470
Total assets	_	104,006,365	96,495,481
LIABILITIES			
CURRENT LIABILITIES			
Other payables	9 _	118,906	117,462
Liabilities (excluding net assets attributable to holders of			
participating redeemable shares) Net assets attributable to holders of participating		118,906	117,462
redeemable shares	3 & 11	103,887,359	96,377,919
Total liabilities	_	104,006,265	96,495,381
SHAREHOLDERS' EQUITY			
Management shares	10	100	100
Total equity	_	100	100
Total equity and liabilities	=	104,006,365	96,495,481
Net asset value per participating redeemable share	11	1.41	1.31

The notes 1 to 16 on pages 17 to 31 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 30 November 2023 and signed on its behalf by:

Marie Curutchet

Director

Robert Rhodes

Director



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Comprehensive Income

	Notes	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
INCOME			
Net realised gain on financial assets at fair value through profit or loss Change in unrealised gain/(loss) on financial assets at fair value through	6	435,523	414,711
profit or loss	6	8,271,689	(13,528,402)
Net gains/(losses) on financial assets at fair value through profit or loss	·	8,707,212	(13,113,691)
Deposit interest		58,143	-
Dividend income		24,491	25,987
Other foreign exchange loss		-	(4)
Other loss		-	(1)
Total net income/(loss)		8,789,846	(13,087,709)
OPERATING EXPENSES			
Audit fee		(4,693)	(7,649)
Transfer agent fee		(81)	(126)
Custodian fee	13	(35,789)	(44,051)
Investment Management fee	13	(942,296)	(1,011,069)
Management and Administration fee	13	(222,823)	(234,560)
Sundry expenses		(7,736)	(7,955)
Total operating expenses		(1,213,418)	(1,305,410)
Net profit/(loss) before tax		7,576,428	(14,393,119)
Increase/(decrease) in net assets attributable to holders of	•		
participating redeemable shares from operations	;	7,576,428	(14,393,119)

All items in the above statement derive from continuing operations. There is no difference between the increase/(decrease) in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 16 on pages 17 to 31 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Cash Flows

	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations	7,576,428	(14,393,119)
ADJUSTMENTS FOR:		
Net realised gain on financial assets at fair value through profit or loss	(435,523)	(414,711)
Net unrealised (gain)/loss on financial assets at fair value through profit or loss	(8,271,689)	13,528,402
Effect of foreign exchange rate on cash	-	4
Dividend income	(24,491)	(25,987)
Deposit interest	(58,143)	_
Operating loss before working capital changes	(1,213,418)	(1,305,411)
Net decrease/(increase) in other receivables	68	(88)
Net increase/(decrease) in other payables	1,444	(15,649)
Purchase of financial assets at fair value through profit or loss	(24,491)	(8,817,795)
Sale of financial assets at fair value through profit or loss	3,000,000	2,911,636
Dividend received	24,491	25,987
Deposit interest	50,653	<u>-</u>
Net cash generated from/(used in) operating activities	1,838,747	(7,201,320)
CASH FLOW FROM FINANCING ACTIVITIES		
Cash received from issuance of participating redeemable shares	3,872,291	7,849,067
Cash paid on redemption of participating redeemable shares	(3,939,279)	(2,397,999)
Net cash (used in)/generated from financing activities	(66,988)	5,451,068
Net increase/(decrease) in cash and cash equivalents	1,771,759	(1,750,252)
Cash and cash equivalents at the beginning of the year	1,217,145	2,967,401
Effect of foreign exchange rate on cash	-	(4)
Cash and cash equivalents at the end of the year	2,988,904	1,217,145

The notes 1 to 16 on pages 17 to 31 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

	Note	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
Net assets attributable to holders of participating redeemable shares at			
the beginning of the year		96,377,919	105,319,970
Proceeds from issuance of participating redeemable shares		3,872,291	7,849,067
Payments on redemption of participating redeemable shares		(3,939,279)	(2,397,999)
Increase/(decrease) in net assets attributable to holders of participating			
redeemable shares from operations		7,576,428	(14,393,119)
Net assets attributable to holders of participating redeemable shares at			
the end of the year	11	103,887,359	96,377,919

The notes 1 to 16 on pages 17 to 31 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

1. General information

The PB Global Flexible Fund IC Limited (the "Incorporated Cell" or "Cell"), with company number 56162, is a Guernsey registered, Limited Liability Incorporated Cell of the Momentum Mutual Fund ICC Limited (the "Company").

The Cell aims to provide capital appreciation in real terms over the investment horizon. The Cell is ideally suited to investors with an investment horizon of 5 years or longer, and a moderate risk tolerance (measured in the Base Currency of the Cell) over this period. The Investment Manager will tolerate short-term volatility in order to achieve the investment goal of long-term real returns.

The Cell intends to achieve its investment objective through a diversified global portfolio primarily consisting of investments in participatory interests of portfolios of collective investment schemes or other similar schemes. The Cell will invest in participatory interests of underlying portfolios which provide exposure to a wide range of asset classes including cash and/or money market instruments, bonds, international equities, commodities and property. The Cell may also invest in participatory interests of underlying asset allocation portfolios which provide exposure to a combination of the asset classes. The Cell may also invest in transferable securities. The portfolio has flexibility in terms of currencies and asset allocation both between and within asset classes, countries and regions.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager"), and Portfolio Bureau Investments (Pty) Limited acting as the Sub-Investment Manager.

On 1 November 2022, minor adjustments were made to the Supplemental Prospectus of the Cell.

The financial statements were authorised for issue by the Board of Directors on 30 November 2023.

2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards ("IFRS"). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

Going concern

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2024 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.2 Adoption of new and revised standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2022:

(a) IFRS 9 - Fees in the '10 per cent ' Test for Derecognition of Financial Liabilities - Amendment to clarify the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

(b) IFRS 3 - Updating a Reference to the Conceptual Framework - Amendments updated IFRS 3 by replacing a reference to an old version of the Board's Conceptual Framework for Financial Reporting with a reference to the latest version.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

Standards, amendments and interpretations in issue not yet effective

A number of new standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2023 and have not been early adopted in preparing these financial statements. These include:

- (a) IAS 1 Definition of Accounting Estimates (Amendments to IAS 8) Effective from 1 January 2023 Amendments regarding classification of liabilities and disclosure of accounting policies.
- (b) IAS 1 Disclosure Initiative Accounting Policies Effective from 1 January 2023 Amendments to help entities apply materiality judgements to accounting policy disclosure.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

2.3 Foreign currency translation

(a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Cell, and in doing so, have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represents the functional currency.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.3 Foreign currency translation (continued)

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.

2.4 Financial assets and financial liabilities at fair value through profit or loss

(a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

(b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

(c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

(d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bidask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no-par value participating redeemable shares.

(a) Management shares

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 100 Management shares.

(b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 13.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.9 Share capital (continued)

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.

2.11 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to its carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objectives when managing capital is to safeguard its ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

2.12 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

2.13 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

2.14 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

2.15 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2022: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management

3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

The Cell will not include any derivative instruments but may invest in forward foreign currency exchange contracts for the purpose of mitigating exchange rate risk against both the benchmark and the base currency and not for speculative purposes or otherwise.

3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in collective investment schemes. Through its investment in traded securities and instruments, the Cell is subject to market movements in equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored regularly by the Investment Manager and are reviewed by the Board of Directors periodically.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories hence, concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

	2023 % of Net			2022 % of Net
	Fair Value <u>USD</u>	assets	Fair Value <u>USD</u>	assets
Collective Investment Schemes	101,009,569	97.23	95,277,866	98.86
	101,009,569	97.23	95,277,866	98.86

The Cell's market risk is affected by three main components: changes in actual market prices, interest rate and foreign currency exchange rates movements. Interest rate and foreign currency movements are covered in notes 3.3 and 3.5, respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2023	2022
	Change in	Change in
	fair value	fair value
	<u>USD</u>	<u>USD</u>
Collective Investment Schemes	10,100,957	9,527,787
	10,100,957	9,527,787



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management (continued)

3.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risk. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

	2023	2022
	<u>USD</u>	<u>USD</u>
Net financial assets on which no interest is paid	100,898,455	95,160,774
Net floating rate financial assets	2,988,904	1,217,145

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
Movement in net floating rate financial assets	14,945	6,086

3.4 Cash flow risk

The Cell holds a significant amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

3.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments, denominated in currencies other than the US Dollar, the functional currency, therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Where the Cell invests via Collective Investment Funds, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
Net EUR exposure	7	8
Net GBP exposure	(8,384)	(12,484)
Net ZAR exposure	(1,966)	-



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management (continued)

3.5 Currency risk (continued)

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk, however, to date, the Investment Manager and Board of Directors have deemed that such contracts have not been necessary.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2023 <u>USD</u>	2022 <u>USD</u>
EUR exposure	-	-
GBP exposure	(419)	(624)
ZAR exposure	(98)	-

3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by a Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2.

All transactions in listed securities are settled or paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.

3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short-term liquidity requirements, however, to date, the Cell has not entered into such arrangement.

The table on the next page analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management (continued)

3.7 Liquidity risk (continued)

	2023 Less than 1	2022 Less than 1
	month	month
	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	101,009,569	95,277,866
Cash and cash equivalents	2,988,904	1,217,145
Deposit interest receivable	7,490	-
Other receivables	302	370
Other payables	(118,906)	(117,462)
Net assets attributable to holders of participating redeemable shares	(103,887,359)	(96,377,919)
Net liquidity position		_

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The overall strategy of the Cell remains unchanged.

The Cell has no externally imposed capital requirements.

3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and fair values of the financial assets and liabilities of the Cell.

4. Critical accounting estimates and judgments

The fair value of investments is considered to be the quoted, active market prices, or prices supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

5. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

	2023	2022
	<u>USD</u>	<u>USD</u>
Asia	21,024,699	20,033,290
Guernsey	79,984,870	75,244,576
	101,009,569	95,277,866

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.

6. Financial assets at fair value through profit or loss

	2023	2022
	<u>USD</u>	<u>USD</u>
Financial assets at fair value		
Collective Investment Schemes	101,009,569	95,277,866
Total financial assets at fair value through profit or loss	101,009,569	95,277,866
Movement on financial assets at fair value though profit or loss		
Fair value of financial assets at the beginning of the year	95,277,866	102,485,398
Purchases of financial assets	24,491	8,817,795
Sales of financial assets	(3,000,000)	(2,911,636)
Realised gain on sale of financial assets	435,523	414,711
Movement in unrealised gain/(loss) on revaluation of financial assets	8,271,689	(13,528,402)
Fair value of financial assets at the end of the year	101,009,569	95,277,866
Comprising:		
Cost at the end of the year	80,338,355	82,878,341
Unrealised gain at the end of the year	20,671,214	12,399,525
	101,009,569	95,277,866

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

6. Financial assets at fair value through profit or loss (continued)

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2023 and 30 June 2022.

30 June 2023	Level 1 <u>USD</u>	Level 2 <u>USD</u>	Level 3 <u>USD</u>	Total <u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	101,009,569	-	-	101,009,569
	101,009,569	-	-	101,009,569
30 June 2022	Level 1	Level 2	Level 3	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	95,277,866	-	-	95,277,866
	95,277,866	-	-	95,277,866

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2023 and 30 June 2022.

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

7. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2023	2022
	<u>USD</u>	<u>USD</u>
Cash at bank	2,988,904	1,217,145
	2,988,904	1,217,145
8. Other receivables		
	2023	2022
	<u>USD</u>	<u>USD</u>
Prepayments	302	370
Management shares receivable	100	100
	402	470
9. Other payables		
	2023	2022
	<u>USD</u>	<u>USD</u>
Management and Administration fee payable	18,890	18,278
Custodian fee payable	6,942	6,363
Investment Management fee payable	80,596	77,223
Sundry expenses payable	4,094	4,015
Audit fee payable	8,384	11,583
	118,906	117,462

10. Share capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

Management Shares in Issue	2023	2022
	<u>USD</u>	<u>USD</u>
Management shares	100	100
	Year ended	Year ended
Participating Redeemable Shares in Issue - Class A	30.06.23	30.06.22
Balance at the beginning of the year	73,632,968	70,023,457
Issue of participating redeemable shares	2,805,543	5,278,539
Redemption of participating redeemable shares	(2,881,733)	(1,669,028)
Balance at the end of the year	73,556,778	73,632,968



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

11. Net asset value per participating redeemable share

	NAV per	Net assets	Shares	NAV per	Net assets	Shares
	share	attributable	in issue	share	attributable	in issue
As at 30 June	2023	2023	2023	2022	2022	2022
	<u>USD</u>	<u>USD</u>		USD	USD	
Class A	1.41	103,887,359	73,556,778	1.31	96,377,919	73,632,968

12. Dividends payable to participating redeemable shareholders

No dividends were paid during the year (2022: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

13. Related-party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

13.1 Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager is entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD 22,000 or currency equivalent.

Fee - % of NAV per annum	<u>Cell NAV</u>
0.25%	Up to USD50m
0.20%	From USD50m to USD100m
0.15%	Over USD100m

The Administrator is entitled to such remuneration as agreed between the Manager and the Administrator from time to time and such remuneration is paid by the Manager out of the Management and Administration fee received from the Cell.

Management and Administration fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	222,823	234,560
Accrued at year end	18,890	18,278

13.2 Investment Management fee

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell.

The Investment Manager is entitled to receive a fee, charged at a rate equal to 0.95% of the NAV of the Cell and the Sub- Investment Management fee will be equal to 0.85% of the NAV of the Cell. The Sub-Investment Management fee will be paid from the fee received by the Investment Manager.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

13. Related-party transactions (continued)

13.2 Investment Management fee (continued)

The Investment Manager appointed Portfolio Bureau Investments (Pty) Limited, a South African registered company, as Sub-Investment Manager (the "Sub-Investment Manager") to the Cell and to any Trading Subsidiaries of the Cell. The Sub-Investment Manager is entitled to receive a fee equal to 0.85% of the NAV of the Cell attributable to the Class A USD Shares per annum "the Sub-Investment Management fee", which will be paid out of the fee received by the Investment Manager. The Sub-Investment Management Fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears.

Investment Management fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	942,296	1,011,069
Accrued at year end	80,596	77,223

13.3 Custodian fee

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The Custodian is entitled to the payment of a fee (the "Custodian fee") chargeable on a sliding scale in respect of all Share Classes, as follows, subject to a minimum of USD8,000 per annum.

Fee - % of NAV per annum	<u>Cell NAV</u>
0.05%	Up to USD30 million
0.04%	From USD30 million to USD60 million
0.03%	From USD60 million to USD100 million
0.02%	Over USD100 million

Custodian fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	35,789	44,051
Accrued at year end	6,942	6,363

13.4 Board of Director's remuneration

The Directors' fees in respect of the Cell shall not exceed USD20,000 or currency equivalent in any twelve month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other cells of the Company or assets of the Company itself.

The Directors waived their right to a fee in 2023 (2022: Nil).

14. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

15. Reconciliation of published valuation to financial statements

	2023 <u>USD</u>	2022 <u>USD</u>
Net assets attributable to holders of participating redeemable shares per financial statements Adjustments:	103,887,359	96,377,919
Adjustment to accrue for rebranding fees Adjustment in value of assets at financial assets at fair value through profit and loss Not assets attributable to helders of participating radiographs above par	(326,744)	441 331,227
Net assets attributable to holders of participating redeemable shares per published valuation	103,560,615	96,709,587
NAV per Class A per published valuation NAV per Class A per financial statements	1.41 1.41	1.31 1.31

16. Subsequent events

These financial statements were approved for issuance by the Board on 30 November 2023. Subsequent events have been evaluated until this date.

No significant subsequent events have occurred in respect of the Cell that is considered material to the understanding of these audited financial statements.